The Danish pharmaceutical giant Novo Nordisk plummeted by around ten percent on the Copenhagen Stock Exchange, but recovered somewhat and closed at minus 7.4 percent.
The reason for the setback is primarily new drug studies from the competitor, American Eli Lilly. Both companies are giants in weight loss medication. The study shows that Eli Lilly's pills have approximately the same effect as Novo's preparation Ozempic.
The previously successful stock Novo Nordisk has lost around a third of its stock market value since the turn of the year.
